- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00343070
Functional Neuroimaging in Depression
August 30, 2010 updated by: University Hospital, Ghent
Functional Neuroimaging in Depression: Longitudinal Study of PET Metabolism in Correlation With Changes in Attentional Bias, Autobiographical Memory, Future Fluency and Facial Recognition in Depressed Patients Treated With Escitalopram.
Oral administration of escitalopram during 8 weeks; PET scan with 18F-FDG at inclusion and after 8 weeks
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
40
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Ghent, Belgium, 9000
- University Hospital Ghent
-
Kortrijk, Belgium, 8500
- AZ Groeninge campus Sint Maarten
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Major Depression, Depressive episode, following DSM-IV criteria
- MADRS-score > 25
- Age: 18-65 yrs
- Medication-free or anti-depressant wash-out 7 days (for fluoxetine: 6 weeks)
- Lorazepam 1mg or zolpidem 10mg are allowed
Exclusion Criteria:
- Suicidality
- Bipolar disorder, following DSM-IV criteria
- Psychotic symptoms
- Substance abuse
- Personality disorder, following DSM-IV criteria
- Cognitive dysfunction due to trauma capitis or dementia
- Diabetes mellitus
- Women without contraceptive protection, with pregnancy or breast feeding
- Pharmacological treatment or ingestion of substance that can influence cerebral perfusion less than a month before inclusion
- IQ below 80
- Conditions not compatible with SPC
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Brain metabolism
|
Secondary Outcome Measures
Outcome Measure |
---|
Cognitive functions
|
Efficacy scales (mood, anxiety, anger and hopelessness)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Kurt Audenaert, MD, PhD, University Hospital, Ghent
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2007
Primary Completion (Actual)
October 1, 2009
Study Completion (Actual)
October 1, 2009
Study Registration Dates
First Submitted
June 19, 2006
First Submitted That Met QC Criteria
June 20, 2006
First Posted (Estimate)
June 22, 2006
Study Record Updates
Last Update Posted (Estimate)
August 31, 2010
Last Update Submitted That Met QC Criteria
August 30, 2010
Last Verified
August 1, 2010
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Behavioral Symptoms
- Mental Disorders
- Mood Disorders
- Depression
- Depressive Disorder
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Psychotropic Drugs
- Serotonin Uptake Inhibitors
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Serotonin Agents
- Antidepressive Agents
- Antidepressive Agents, Second-Generation
- Citalopram
Other Study ID Numbers
- 2006/176
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Major Depression
-
Stanford UniversityTerminatedMajor Depressive Disorder | Major Depressive Episode | Major Depressive Disorder, Recurrent | Major Depression Mild | Major Depression Moderate | Major Depression SevereUnited States
-
Hawler Medical UniversityCompleted
-
Centre Hospitalier Universitaire de BesanconH. Lundbeck A/SCompletedResistant Major DepressionFrance
-
First Affiliated Hospital of Zhejiang UniversityNot yet recruiting
-
University of PittsburghCompletedPostpartum Major DepressionUnited States
-
Si TianmeiUnknownMajor Depression DisorderChina
-
The Hong Kong Polytechnic UniversityNot yet recruitingHealthy | Major Depression in Remission
-
AstraZenecaCompletedNon-psychotic Unipolar Major DepressionArgentina
-
Ruijin HospitalTerminatedTreatment Resistant Major Depression DisorderChina
-
Zentrum für Integrative PsychiatrieGerman Research FoundationCompletedCognitive Performance in Major DepressionGermany
Clinical Trials on Oral administration of escitalopram during 8 weeks
-
Fuji Yakuhin Co., Ltd.Completed
-
University of PennsylvaniaWashington University School of MedicineCompleted
-
Universidade Federal do Rio de JaneiroCompletedAssessment of Muscle Architecture and Tendon After Chronic Stretching ProgramBrazil
-
Medical College of WisconsinChildren's Hospital and Health System Foundation, Wisconsin; Santosh Yoga LLCTerminated
-
H. Lundbeck A/STerminated
-
Michigan State UniversityThe Board of MedicineRecruitingAttention Deficit Disorder With HyperactivityUnited States
-
GlaxoSmithKlineCompleted
-
Virginia Commonwealth UniversityCompletedPregnancy Related | Contraception | Contraception Behavior | Contraception Use
-
Laval UniversityActive, not recruitingMetabolic Syndrome | Gut MicrobiotaCanada
-
Merck Sharp & Dohme LLCCompleted